Dyslexia Treatment and Diagnosis Market Size, Share & Trends Analysis Report By Type (Phonological Dyslexia, Surface Dyslexia, Double Deficit Dyslexia, Others), By Drug Class (Antihistamines, Central Nervous Stimulant, Selective Norepinephrine Reputake Inhibitors, Others), By End-User (Psychiatric Institutions, Rehabilitation Centres, Home Care, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Dyslexia Treatment and Diagnosis Market Size

The global dyslexia treatment and diagnosis market size was valued at USD 32.73 billion in 2025 and is projected to grow from USD 35.12 billion in 2026 to USD 61.71 billion by 2034, registering a CAGR of 7.3% during the forecast period from 2026 to 2034. North America dominated the dyslexia treatment and diagnosis market with a market share of 38.6% in 2025.

Greater awareness and understanding of dyslexia among healthcare professionals, educators, and the general public drive demand for diagnosis and treatment options. Efforts to educate parents, teachers, and healthcare providers about dyslexia symptoms, early signs, and intervention strategies contribute to market growth.

Dyslexia is a condition when the patient struggles with writing, reading, and remembering unfamiliar or complicated words. Dyslexia is a neurological learning disorder found in various regions of people. Early management of dyslexia in children is possible with the use of specialized educational methods. In addition, various online programs and tools assist in improving the reading and learning problems of dyslexia disorder. The underlying brain variations that lead to dyslexia cannot yet be treated, but success can be increased with early discovery, examination, and selection of the most suitable therapy. Dyslexia is the most prevalent type of learning disability in children. Treatment often enables kids to develop their reading skills.

Type Analysis

The market is segmented into phonological dyslexia, surface dyslexia, double deficit dyslexia, and others.

Phonological dyslexia segment is dominating in the market. This dominance is due to two key factors. First, phonological dyslexia are the most common type, affecting about 70% of dyslexia. This type of people has difficulties connecting letters to sounds and vice versa. Second, there are well-established interventions designed specifically for phonological dyslexia, such as phonological awareness training, that are effective in improving reading skills. Although there are other types of dyslexia, such as superficial and dual deficiency dyslexia, they are less common and treatments are still being developed. The Other category includes these less common variants.

Request Customizationto receive a tailored report.

Drug Class Analysis

The market is segmented into antihistamines, central nervous stimulant, selective norepinephrine reputake inhibitors, and others.

Unlike other conditions, medication is not the main treatment for dyslexia. The focus is on educational and therapeutic interventions. However, there are some medications on the market that are used to treat co-morbidities that are sometimes associated with dyslexia. There is no single dominant drug class here, as the choice depends on the specific problem. For example, in case of allergies, antihistamines can be prescribed, which prevent concentration during treatment. Central nervous system stimulants such as methylphenidate may be used if someone with dyslexia also has ADHD to improve concentration. Selective norepinephrine reuptake inhibitors (SNRIs) may be used to treat co-occurring anxiety or depression. The others category includes medications for less common comorbidities. In general, medications play a supportive role and therapeutic interventions remain at the heart of dyslexia treatment.

End-User Analysis

The global market is segmented into specialty centers, home care, hospitals and clinics, and others.

The specialty center segment owns the highest market share and is expected to grow at a CAGR of 6.63% over the forecast period. Specialty centers are specialized settings for the treatment of mental health disorders. Specialty centers have gained demand in cases of dyslexia, as it is observed that children who have dyslexia also suffer from some other psychiatric disorder. According to a report published by Assiut University, Egypt, in July 2020, of children diagnosed with dyslexia, over 60% suffer from at least another psychiatric disorder. Therefore, specialty centers become essential to provide treatment and care for such co-morbid cases of dyslexia.

The home care segment is estimated to grow at a significant CAGR during the forecast period due to the increasing demand for dyslexia treatment methods at home. In-home settings, the child experiences the safest environment, which is ideal for learning. Moreover, ample facilities are available to help improve reading capabilities at home, such as apps, e-readers, virtual consulting sessions, and more.

Speak to an Analystto discuss market opportunities.

Regional Insights

Based on region, the global dyslexia treatment and diagnosis market share is divided into North America, Europe, Asia-Pacific, and the Rest of the World.

North America Dominates the Global Market

North America is the most significant contributor to the global market and is anticipated to grow at a CAGR of 6.15% during the forecast period. The market in the region is driven by a well-developed healthcare infrastructure, supportive governmental laws, substantial regional firm headquarters, like Jubilant Cadista (US) and Speechify (US), and a high prevalence of dyslexia. In addition, a learning-based problem, most frequently dyslexia, affects one in five pupils, or 15% to 20% of the US population, according to the Dyslexia Center of Utah. Additionally, the area is home to several non-profit organizations having a presence worldwide. These groups help sufferers and their families and raise public awareness of dyslexia. Several notable schools in the area cater to dyslexic students. There are over 100 private schools for people with dyslexia in the US and around six in Canada. The education ministries are also implementing policies driving growth for the market.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe: Rapidly Growing Region

Europe is estimated to grow at a CAGR of 7.02% over the forecast period. Similar to North America, dyslexia is widespread in Europe. According to a December 2019 survey from The Institute of Entrepreneurship Development (iED), 15% of people in Europe have dyslexia. Furthermore, a significant portion of the 15% of people with dyslexia also has other co-morbid conditions. In addition to dyslexia, 20 to 40 percent of those with dyslexia also have dyscalculia, and 10 to 20 percent have anxiety issues. In the UK alone, about 6 million people are living. As a result, the region's need for high-quality medical care and diagnostic tools is excellent. Moreover, key players headquartered in the region are innovating and driving growth in the regional market. For instance, GlaxoSmithKline plc (UK) has a project named IT Accessibility Project that focuses on providing IT solutions to users and customers with disabilities, including dyslexia. The company also announced in June 2021 that it would drastically expand its specialty medicines portfolio over the next decade.

Asia-Pacific is the fastest-growing regional market, as it is developing rapidly and has witnessed the emergence of many players. There is a presence of several market players in the region who are driving growth for the market, such as Cian Healthcare Pvt Ltd. (India), Wallace Pharmaceuticals Ltd. (India), and RPG Life Sciences Ltd (India). There is also a high prevalence of dyslexia, driving the market growth. According to the Department of Biotechnology, in 2019, around 35 million children in India were suspected of people with dyslexia.

Additionally, counties in the Asia-Pacific regions have developed their dyslexia assessment tests to correctly identify the dyslexic population within the country and provide appropriate care. For instance, the National Brain Research Centre, India, developed the Dyslexia Assessment for the Languages of India (DALI) assessment test for children from classes 1-5. Similarly, Japan and Indonesia have also developed their dyslexia test battery for children. However, there is a high stigma regarding mental health disorders in the region which restricts people from getting diagnosed.

The rest of the world comprises the Middle East and Africa and Latin America. The rest of the world region showed restricted growth owing to a need for mental health awareness and facilities. In Africa, one in ten people is suspected of having dyslexia. Organizations such as Dyslexia International are running initiatives to train teachers to handle students with dyslexia and facilities like e-learning and campus for dyslexic children in Africa. The region's market growth is majorly due to the presence of developed countries in the Middle East, especially the Gulf countries.

Furthermore, countries like the United Arab Emirates have specialized schools and centers specifically for people with dyslexia in the Middle East. Taleem Training and Skill Development Center and Lexicon Reading Center are examples of the same. Globally accepted dyslexic tests are also being translated into Arabic languages to implement them in these countries. For instance, in Jordan in 2018, the Woodcock-Johnson IV assessment test was translated into Arabic. Such initiatives are driving growth for the regional market.

List of Key and Emerging Players in Dyslexia Treatment and Diagnosis Market